Endothelin antagonism in end-organ damage of spontaneously hypertensive rats - Comparison with angiotensin-converting enzyme inhibition and calcium antagonism

被引:74
|
作者
Karam, H
Heudes, D
Bruneval, P
Gonzales, MF
Loffler, BM
Clozel, M
Clozel, JP
机构
[1] F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,DIV PHARMA,CH-4002 BASEL,SWITZERLAND
[2] HOP BROUSSAIS,INSERM U430,F-75674 PARIS,FRANCE
[3] INSERM U367,PARIS,FRANCE
关键词
angiotensin II; endothelin; kidney; mibefradil; bosentan; enalapril;
D O I
10.1161/01.HYP.28.3.379
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
High blood pressure results in cardiac hypertrophy and fibrosis, increased thickness and stiffness of large artery walls, and decreased renal function. The objective of our study was to assess the role of endothelin, angiotensin II, and high blood pressure in the end-organ damage observed in spontaneously hypertensive rats (SHR). For this purpose, SHR were treated for 10 weeks with either a mixed endothelin-A and endothelin-B receptor antagonist, bosentan (100 mg/kg per day), an angiotensin-converting enzyme inhibitor, enalapril (10 mg/kg per day), or a long-acting calcium antagonist, mibefradil (20 mg/kg per day). A group of SHR was left untreated, and a group of normotensive Wistar rats was used as control. At the end of treatment, maximal coronary blood flow was measured in isolated perfused hearts. Cardiac hypertrophy and fibrosis, aortic medial thickness, and extracellular matrix content were evaluated by quantitative morphometry. Proteinuria and urea and creatinine clearances were measured, and renal histopathology was assessed. SHR exhibited cardiac hypertrophy, perivascular fibrosis, and decreased maximal coronary blood Bow. Aortic medial thickness was increased, whereas elastin density was decreased. Finally, SHR showed decreased urinary excretion and decreased urea and creatinine clearances. No renal histological lesions were observed. Although bosentan did not affect blood pressure, it normalized renal function and slightly decreased left ventricular hypertrophy and fibrosis. Enalapril and mibefradil were both effective in significantly decreasing blood pressure, left ventricular hypertrophy, and aortic medial thickness and improving coronary blood flow, but in contrast to busentan, they did not improve creatinine clearance. The conclude that in SHR, high blood pressure sure plays a major role in end-organ damage and that endothelin may partly mediate renal dysfunction and cardiac remodeling independently of a direct hemodynamic effect.
引用
收藏
页码:379 / 385
页数:7
相关论文
共 50 条
  • [31] ANGIOTENSIN-CONVERTING ENZYME-INHIBITION OR ALDOSTERONE ANTAGONISM REDUCES CYCLOSPORINE NEPHROTOXICITY IN THE RAT
    THOMSON, AW
    MCAULEY, FT
    WHITING, PH
    SIMPSON, JG
    TRANSPLANTATION PROCEEDINGS, 1987, 19 (01) : 1242 - 1243
  • [32] Inhibition of angiotensin-converting enzyme activity by a partially purified fraction of Gynura procumbens in spontaneously hypertensive rats
    Hoe, See-Ziau
    Kamaruddin, Mohd Yusof
    Lam, Sau-Kuen
    MEDICAL PRINCIPLES AND PRACTICE, 2007, 16 (03) : 203 - 208
  • [33] GLOMERULAR DYNAMICS AND MORPHOLOGY OF AGED SPONTANEOUSLY HYPERTENSIVE RATS - EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION
    KOMATSU, K
    FROHLICH, ED
    ONO, H
    ONO, Y
    NUMABE, A
    WILLIS, GW
    HYPERTENSION, 1995, 25 (02) : 207 - 213
  • [34] Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension
    Swales, P
    Williams, B
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2002, 3 (02) : 79 - 89
  • [35] Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension
    Stergiou, GS
    Skeva, II
    Baibas, NM
    Roussias, LG
    Kalkana, CB
    Achimastos, AD
    Mountokalakis, TD
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (06) : 937 - 941
  • [36] DIFFERENTIAL-EFFECTS ON RENAL INJURY BETWEEN ANGIOTENSIN-CONVERTING ENZYME-INHIBITION AND ANGIOTENSIN RECEPTOR ANTAGONISM IN DAHL RATS
    HIRAWA, N
    UEHARA, Y
    NAGATA, T
    OMATA, M
    HYPERTENSION, 1993, 21 (04) : 555 - 555
  • [37] Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
    Mehdi, Uzma F.
    Adams-Huet, Beverley
    Raskin, Philip
    Vega, Gloria L.
    Toto, Robert D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (12): : 2641 - 2650
  • [38] Chronic angiotensin converting enzyme inhibition and angiotensin II antagonism in the remnant kidney model of rats
    Yoshida, K
    Xu, HL
    Kawamura, T
    Ji, L
    Mori, N
    Kohzuki, M
    JOURNAL OF HYPERTENSION, 2002, 20 : S42 - S42
  • [39] Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats
    Colonna, VD
    Rigamonti, A
    Fioretti, S
    Bonomo, S
    Manfredi, B
    Ferrario, P
    Bianchi, M
    Berti, F
    Muller, EE
    Rossoni, G
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 516 (03) : 253 - 259
  • [40] Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester - Correlation with topography of vascular endothelin-1 gene expression
    Li, JS
    Deng, LY
    Grove, K
    Deschepper, CF
    Schiffrin, EL
    HYPERTENSION, 1996, 28 (02) : 188 - 195